Methyl 5-(4-(5-((dimethylamino)methyl)-1-methyl-1H-pyrazol-3-yl)pyrimidin-2-ylamino)-1,7-dimethyl-1H-indazole-3-carboxylate

ID: ALA4744190

Chembl Id: CHEMBL4744190

PubChem CID: 162646994

Max Phase: Preclinical

Molecular Formula: C22H26N8O2

Molecular Weight: 434.50

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  COC(=O)c1nn(C)c2c(C)cc(Nc3nccc(-c4cc(CN(C)C)n(C)n4)n3)cc12

Standard InChI:  InChI=1S/C22H26N8O2/c1-13-9-14(10-16-19(21(31)32-6)27-30(5)20(13)16)24-22-23-8-7-17(25-22)18-11-15(12-28(2)3)29(4)26-18/h7-11H,12H2,1-6H3,(H,23,24,25)

Standard InChI Key:  LIKKXZUFDFQHPC-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4744190

    ---

Associated Targets(Human)

SYK Tclin Tyrosine-protein kinase SYK (7372 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SU-DHL-2 (105 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 434.50Molecular Weight (Monoisotopic): 434.2179AlogP: 2.66#Rotatable Bonds: 6
Polar Surface Area: 102.99Molecular Species: NEUTRALHBA: 10HBD: 1
#RO5 Violations: HBA (Lipinski): 10HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 12.54CX Basic pKa: 7.60CX LogP: 3.03CX LogD: 2.61
Aromatic Rings: 4Heavy Atoms: 32QED Weighted: 0.46Np Likeness Score: -1.41

References

1. Grimster NP,Gingipalli L,Barlaam B,Su Q,Zheng X,Watson D,Wang H,Simpson I,Pike A,Balazs A,Boiko S,Ikeda TP,Impastato AC,Jones NH,Kawatkar S,Kemmitt P,Lamont S,Patel J,Read J,Sarkar U,Sha L,Tomlinson RC,Wang H,Wilson DM,Zehnder TE,Wang L,Wang P,Goldberg FW,Shao W,Fawell S,Dry H,Dowling JE,Edmondson SD.  (2020)  Optimization of a series of potent, selective and orally bioavailable SYK inhibitors.,  30  (19): [PMID:32717371] [10.1016/j.bmcl.2020.127433]

Source